



Increase in siRNA activity and more potent RNAi response


Maina, A.; Blackman, B.A.; Parronchi, C.J.; Morozko, E.; Bender, M.E.; Blake, A.D.; Sabatino D. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 5270-5274.



Patel, M.R.; Kozuch, S.D.; Cultrara, C.N.; Yadav, R.; Huang, S.; Samuni, U.; Koren, J.; Chiosis, G.; Sabatino, D. *Nano Lett.*, **2016**; *16*, 6099–6108.



Cultrara, C.N.; Shah, S.; Kozuch, S.D.; Patel, M.R.; Sabatino, D. *Chem. Biol. Drug Des.* **2019**; 93, 999-1010.



Cultrara, C.N.; Kozuch, S.D.; Heller, C.J.; Ramasundaram, P.; Shah, S.; Beck, A.E.; Sabatino, D.; Zilberman, J. *BMC Cancer* **2018**: 18, 1263.

Fig 1. RNA synthetic biology for cancer gene therapy (aim I). A. Branch and hyperbranch siRNAs, B. RNA self-assembly and siRNA nanostructures, C. RNA bioconjugation of bioactive probes and self-assembly of GRP silencing siRNA, D. Change in PC3 cells' morphology and adhesion to OSB cells with GRP78-siRNA treatment.